Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus platinum-etoposide chemoradiotherapy versus platinum-etoposide chemoradiotherapy in limited-stage small cell lung cancer
2024-513433-20-00Phase 2Authorised
- Sponsor
- University Medical Center Mainz
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab, cisplatin, carboplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by University Medical Center Mainz. Primary endpoint: Progression-free survival after 18 months. Planned start Sep 2024; status: authorised.
02
Drugs
durvalumabcisplatincarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-513433-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513433-20-00.